| Price | Lot Size | Issue Date | Issue Size |
|---|---|---|---|
| ₹938 to ₹988 | 15 | 24th Aug, 2026 – 27th Aug, 2026 | ₹1757 Cr |
Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd. is an R&D-driven pharmaceutical and biotechnology company with capabilities spanning organic chemistry, biotechnology and complex injectables. Established in 1995 as a steroidal-hormone API manufacturer, the company has evolved into a backwards-integrated, global-scale platform with approvals from the US FDA, EU-GMP, WHO-GMP and other major regulatory authorities. Symbiotec has established a leadership position in corticosteroid and steroidal-hormone APIs, commanding a global volume market share of 38% in corticosteroids and 23% in steroidal-hormone APIs in FY26. Its portfolio covers 60+ molecules across sterile and non-sterile formats, with strong positions in Hydrocortisone, Testosterone and Methylprednisolone. The company is uniquely positioned across the top 10 corticosteroid and steroidal-hormone APIs, providing meaningful scale and product diversification. With over 80% of its portfolio by revenue supported by make-versus-buy capabilities, backward integration helps reduce dependence on external suppliers and imported intermediates while improving cost competitiveness and supply reliability. As of March 2026, Symbiotec operated manufacturing facilities across Rau, Pithampur, Ujjain and Mhow, with aggregate capacities of 584.7 MT in chemical synthesis, 700 KL in fermentation and 20mn complex-injectable vials annually. Its regulatory and customer franchise remains strong, with 43 USFDA DMFs, 23 EDQM CEPs and 200+ customers across 40+ countries. The company also benefits from established customer relationships, with an average tenure of its top customers exceeding ten years. The company is further investing in higher-growth, high-barrier adjacencies, including biologics such as GLP-1 and insulin, complex injectables and niche APIs such as conjugated estrogen. Supported by 156 scientists and engineers across three R&D centres, these initiatives provide a pathway to diversify beyond its core steroidal franchise and strengthen its long-term growth profile.
Objective of Symbiotec Pharmalab Ltd
The net proceeds from the fresh issue will be used towards the following purposes:
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company; and
- General corporate purposes. General corporate purposes.
Rationale To Symbiotec Pharmalab Ltd
Investment Rationale
Global Leadership in Corticosteroid and Steroidal-Hormone APIs
Symbiotec’s global leadership in corticosteroid and steroidal-hormone APIs provides a strong competitive moat and remains the core pillar of its investment case. The company held 38.2% global volume market share in corticosteroids and 23.8% in steroidal-hormone APIs in FY26, while being the only global player with a presence across the top 10 products in these categories. Its portfolio of 60+ APIs spans ~90% of the relevant product universe, providing significant breadth across sterile and non-sterile formats. The company has particularly strong positions in Hydrocortisone, Testosterone and Methylprednisolone, where it commanded 80.1%, 76.4% and 76.0% global volume market shares, respectively, in FY26. This leadership is supported by differentiated steroidal chemistry capabilities, including the ability to execute up to 400 validated cGMP synthesis steps, along with 43 US FDA DMFs and 23 EDQM CEPs, strengthening its regulatory entry barriers and global customer access. A key differentiator is Symbiotec’s backward-integrated farm/microbe-to-pharmacy model, supported by 700 KL fermentation capacity and in-house manufacturing of key steroidal precursors. The ability to make strategic make-versus-buy decisions for KSMs covering over 80% of portfolio revenue reduces dependence on external suppliers and imports, while supporting cost competitiveness and supply reliability. With demand for corticosteroids supported by the rising prevalence of inflammatory and autoimmune conditions and steroidal hormones benefiting from reproductive health, metabolic disorders and hormone-replacement therapies, the addressable market remains structurally attractive. Further, investments of Rs. 799 crores over the last three fiscals in API and injectable capabilities should support capacity expansion and product diversification. The company market leadership, deep chemistry capabilities, backward integration and regulatory track record provide a strong foundation to defend its franchise and capture incremental growth in high-value steroidal APIs.
Long-standing Customer Relationships Provide Revenue Visibility
Symbiotec’s diversified and sticky customer base provides meaningful revenue visibility and supports the resilience of its API franchise. As of March 2026, the company served 200+ customers across 40+ countries, including over 50 domestic and 150 export customers, with continued customer additions of 101, 96 and 89 in FY26, FY25 and FY24, respectively. Customer stickiness is particularly strong in corticosteroid and steroidal-hormone APIs, where complex chemistry, multi-step manufacturing processes and stringent regulatory requirements create high switching costs. Any change in API suppliers typically requires product validation, regulatory filings and approvals, making supply reliability and an established compliance track record key selection criterion for customers. This is reflected in Symbiotec’s average relationship tenure of over 10 years with its top five and top 10 customers as of March 2026. Further, the company has been expanding its product offerings to existing customers, creating opportunities for deeper wallet share. We believe the combination of long customer relationships, high switching costs, consistent quality and backward-integrated supply capabilities provides strong customer retention and supports sustainable growth in its core API franchise.
Valuation of Symbiotec Pharmalab Ltd
Symbiotec Pharmalab is a pharmaceutical and biotechnology company focused on APIs, corticosteroids and steroidal hormones, with capabilities in biotechnology, CDMO and complex injectables. Headquartered in Indore, Madhya Pradesh, it serves 200+ customers across 40+ countries. In FY26, 67% of revenue came from overseas markets out of which Europe stood at 29%, US at 13%, and rest of global revenues at 25%; while India contributed 33%. Its portfolio includes 60+ corticosteroid and steroidal-hormone APIs, alongside fermentation products, biologics and complex injectables. The top five products of Symbiotec are progesterone, hydrocortisone, testosterone, betamethasone and methylprednisolone which accounted for 62% of FY26 revenue. The company is expanding into complex injectables, biotechnology and contract development and manufacturing organization (CDMO), supported by its Ujjain and Mhow facilities, which take total fermentation capacity to 700 KL. On the financial front, Symbiotec has demonstrated steady financial performance, with Revenue, EBITDA and PAT registering CAGRs of 10%, 14% and 5%, respectively, during FY24-FY26. The company’s strong positioning in steroidal APIs, backward-integrated manufacturing model and diversified presence across 40+ countries provide a strong base for sustained growth. At the issue price of Rs. 988, the IPO is valued at 52x FY26 diluted EPS of Rs. 19, representing a meaningful discount to the peer average. Given Symbiotec’s market leadership in steroidal APIs, strong customer relationships, backward integration and potential from emerging businesses, we believe the valuation offers an attractive entry point relative to its growth and diversification prospects. We thus recommend a “SUBSCRIBE” rating to the issue.
What is the Symbiotec Pharmalab Ltd IPO?
The initial public offer (IPO) of Symbiotec Pharmalab Ltd an early investment opportunity in. A stock market investor can buy Symbiotec Pharmalab Ltd IPO shares by applying in IPO before Symbiotec Pharmalab Ltd shares get listed at the stock exchanges. An investor could invest in Symbiotec Pharmalab Ltd for short term listing gain or a long term.
How to apply for the Symbiotec Pharmalab Ltd IPO through StoxBox?
To apply for the Symbiotec Pharmalab Ltd IPO through StoxBox one can apply from the website and also from the app. Click here
When will the Symbiotec Pharmalab Ltd IPO open?
Symbiotec Pharmalab Ltd IPO is opening on 24th Aug 2026. Apply Now
What is the lot size of the Symbiotec Pharmalab Ltd IPO?
The Lot Size of Symbiotec Pharmalab Ltd 15 equity shares. Login to your account now.
When is the Symbiotec Pharmalab Ltd IPO allotment date?
The allotment Date for Symbiotec Pharmalab Ltd IPO is 28th Aug 2026. Login to your account now.
When is the Symbiotec Pharmalab Ltd IPO listing date?
The listing Date for Symbiotec Pharmalab Ltd is 1st Sep 2026. Login to your account now
What is the minimum investment required for the Symbiotec Pharmalab Ltd IPO?
In the Retail segment the minimum investment required is Rs 14,820 Login to your account now
What is the maximum investment allowed for Symbiotec Pharmalab Ltd IPO?
In the Retail segment the maximum investment requirement Rs 1,92,660 Login to your account now
What are the risks associated with investing in the Symbiotec Pharmalab Ltd IPO?
- Symbiotec remains heavily dependent on its API business, which contributed 96.1% of FY26 revenue, while its top five APIs accounted for 62.3%. Any decline in demand, pricing pressure or production disruption in key products could materially impact revenue, profitability and cash flows.
- The company manufacturing facilities are subject to periodic inspections by regulatory authorities and customers. Any quality or compliance failure could lead to regulatory action, production disruptions and reputational damage, adversely impacting revenue, profitability and cash flows.
- The company derives a significant share of revenue from international markets, with exports contributing 67.0% of FY26 revenue. Exposure to currency fluctuations, geopolitical developments, trade restrictions and regulatory changes across overseas markets could adversely impact sales, margins and cash flows.
When will the Symbiotec Pharmalab Ltd IPO shares be credited to my Demat account?
The Symbiotec Pharmalab Ltd will be credited to the account on allotment date which is 28th Aug 2026. Login to your account now
Where can I find the Symbiotec Pharmalab Ltd IPO prospectus?
The prospectus of Symbiotec Pharmalab Ltd IPO prospectus can be found on the website of SEBI, NSE and BSE
